163 related articles for article (PubMed ID: 36180086)
1. Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry.
Metzenmacher M; Griesinger F; Hummel HD; Elender C; Schäfer H; de Wit M; Kaiser U; Kern J; Jänicke M; Spring L; Zacharias S; Kaiser-Osterhues A; Groth A; Hipper A; Zaun G; Dörfel S; Güldenzoph B; Müller L; Uhlig J; Thomas M; Sebastian M; Eberhardt WEE;
Eur Respir J; 2023 Feb; 61(2):. PubMed ID: 36180086
[TBL] [Abstract][Full Text] [Related]
2. M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.
Park H; Dahlberg SE; Lydon CA; Araki T; Hatabu H; Rabin MS; Johnson BE; Nishino M
Oncologist; 2019 Aug; 24(8):e749-e754. PubMed ID: 30696724
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of M descriptors of the 8th edition of TNM classification of lung cancer.
Dias M; Antunes A; Campainha S; Conde S; Barroso A
J Thorac Dis; 2017 Mar; 9(3):685-691. PubMed ID: 28449476
[TBL] [Abstract][Full Text] [Related]
4. Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan.
Sakai K; Kuramoto J; Kojima A; Nishimura H; Kuwabara Y; Toda M; Kobayashi Y; Kikuchi S; Hirata Y; Mikami-Saito Y; Mikami S; Kyoyama H; Moriyama G; Gemma A; Uematsu K
Int J Clin Oncol; 2019 Dec; 24(12):1549-1557. PubMed ID: 31452019
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer.
Shin J; Keam B; Kim M; Park YS; Kim TM; Kim DW; Kim YW; Heo DS
J Thorac Oncol; 2017 Mar; 12(3):520-528. PubMed ID: 27867003
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of the M1b and M1c descriptors from the proposed TNM 8 classification of lung cancer.
Tufman A; Kahnert K; Kauffmann-Guerrero D; Manapov F; Milger K; Müller-Lisse U; Winter H; Huber RM; Schneider C
Strahlenther Onkol; 2017 May; 193(5):392-401. PubMed ID: 28246699
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors.
Liu S; Zhou F; Liu Z; Xiong A; Jia Y; Zhao S; Zhao C; Li X; Jiang T; Han R; Qiao M; Liu Y; He Y; Li J; Li W; Gao G; Ren S; Su C; Zhou C
Transl Lung Cancer Res; 2020 Aug; 9(4):1053-1066. PubMed ID: 32953484
[TBL] [Abstract][Full Text] [Related]
8. Tumor, node and metastasis classification of lung cancer--M1a versus M1b--analysis of M descriptors and other prognostic factors.
Sánchez de Cos Escuín J; Abal Arca J; Melchor Íñiguez R; Miravet Sorribes L; Núñez Ares A; Hernández Hernández JR; García Arangüena L; Núñez Delgado M; Pavón Fernández MJ; Francisco Corral G; de Esteban Júlvez L; González Budiño MT; Abad Cavaco F; Ansótegui Barrera E; Andreo García F; Serra Mitjans M; Hernández Rodríguez H
Lung Cancer; 2014 May; 84(2):182-9. PubMed ID: 24629637
[TBL] [Abstract][Full Text] [Related]
9. Image-based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma.
Shen L; Li W; Wang S; Xie G; Zeng Q; Chen C; Shi F; Zhang Y; Wu M; Shu W; Pan C; Xia Y; Wu P
Radiology; 2016 Sep; 280(3):805-14. PubMed ID: 27023116
[TBL] [Abstract][Full Text] [Related]
10. The TNM 8 M1b and M1c classification for non-small cell lung cancer in a cohort of patients with brain metastases.
Nieder C; Hintz M; Oehlke O; Bilger A; Grosu AL
Clin Transl Oncol; 2017 Sep; 19(9):1141-1146. PubMed ID: 28357633
[TBL] [Abstract][Full Text] [Related]
11. Subdivision of M category for nasopharyngeal carcinoma with synchronous metastasis: time to expand the M categorization system.
Shen LJ; Wang SY; Xie GF; Zeng Q; Chen C; Dong AN; Huang ZM; Pan CC; Xia YF; Wu PH
Chin J Cancer; 2015 Aug; 34(10):450-8. PubMed ID: 26264052
[TBL] [Abstract][Full Text] [Related]
12. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.
Hendriks LE; Derks JL; Postmus PE; Damhuis RA; Houben RM; Troost EG; Hochstenbag MM; Smit EF; Dingemans AM
Eur J Cancer; 2015 Nov; 51(17):2534-44. PubMed ID: 26323530
[TBL] [Abstract][Full Text] [Related]
13. Predicted outcomes of subdividing M1-stage metastatic lung cancer based on the prognosis and the response to local consolidative therapy.
Wang F; Gao J; Ren Y; Su H; She Y; Xie D; Chen C
Ann Transl Med; 2021 Aug; 9(16):1293. PubMed ID: 34532430
[TBL] [Abstract][Full Text] [Related]
14. Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
Heesterman BL; van der Poel HG; Schoots IG; Mehra N; Aben KKH
BJU Int; 2022 Aug; 130(2):217-225. PubMed ID: 34741789
[TBL] [Abstract][Full Text] [Related]
15. Effect of M1a and M1b category in metastatic colorectal cancer.
Kennecke H; Yu J; Gill S; Cheung WY; Blanke CD; Speers C; Woods R
Oncologist; 2014 Jul; 19(7):720-6. PubMed ID: 24899642
[TBL] [Abstract][Full Text] [Related]
16. [Value of surgery for stage IIIa non-small cell lung cancer].
Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of different extrathoracic metastasis patterns in patients with M1c lung adenocarcinoma receiving immunotherapy.
Hu F; Peng J; Mao X; Niu Y; Ma M; Zhao Y; Gu A; Jiang L
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3171-3184. PubMed ID: 35882652
[TBL] [Abstract][Full Text] [Related]
18. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
19. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
[TBL] [Abstract][Full Text] [Related]
20. Impact of a Contralateral Tumor Nodule on Survival in Non-Small-Cell Lung Cancer.
Morris ZS; Cannon DM; Morris BA; Bentzen SM; Kozak KR
J Thorac Oncol; 2015 Nov; 10(11):1608-15. PubMed ID: 26317917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
